ASCO 2011: MDxHealth’s brain cancer companion diagnostic proves itself in Phase III study
This article was originally published in Clinica
Executive Summary
PredictMDx for Brain, a companion diagnostic developed by personalised cancer test specialist MDxHealth, has demonstrated its ability to identify glioblastoma patients who are most responsive to treatment.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.